ELOXATIN Drug Patent Profile

Which patents cover Eloxatin, and what generic alternatives are available?

Eloxatin is a drug marketed by Sanofi Aventis Us and is included in two NDAs.

The generic ingredient in ELOXATIN is oxaliplatin. There are twenty-six drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the oxaliplatin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Eloxatin

A generic version of ELOXATIN was approved as oxaliplatin by HOSPIRA WORLDWIDE on August 7^th, 2009.

Summary for ELOXATIN

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Clinical Trials:	333
DailyMed Link:	ELOXATIN at DailyMed

Recent Clinical Trials for ELOXATIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Puma Biotechnology, Inc.	Phase 2
First Affiliated Hospital of Guangxi Medical University	Phase 2
Mayo Clinic	Phase 1

See all ELOXATIN clinical trials

Paragraph IV (Patent) Challenges for ELOXATIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ELOXATIN	Injection	oxaliplatin	5 mg/mL, 40 mL vials	021759	1	2007-07-16
ELOXATIN	Injection	oxaliplatin	5 mg/mL, 10 mL and 20 mL vials	021759	11	2007-02-09

US Patents and Regulatory Information for ELOXATIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	ELOXATIN	oxaliplatin	INJECTABLE;INTRAVENOUS	021492-001	Aug 9, 2002		DISCN	Yes	No
Sanofi Aventis Us	ELOXATIN	oxaliplatin	INJECTABLE;INTRAVENOUS	021759-002	Jan 31, 2005		DISCN	Yes	No
Sanofi Aventis Us	ELOXATIN	oxaliplatin	INJECTABLE;INTRAVENOUS	021759-001	Jan 31, 2005		DISCN	Yes	No
Sanofi Aventis Us	ELOXATIN	oxaliplatin	INJECTABLE;INTRAVENOUS	021492-002	Aug 9, 2002		DISCN	Yes	No
Sanofi Aventis Us	ELOXATIN	oxaliplatin	INJECTABLE;INTRAVENOUS	021759-003	Nov 17, 2006		DISCN	Yes	No

Expired US Patents for ELOXATIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	ELOXATIN	oxaliplatin	INJECTABLE;INTRAVENOUS	021492-002	Aug 9, 2002
Sanofi Aventis Us	ELOXATIN	oxaliplatin	INJECTABLE;INTRAVENOUS	021759-003	Nov 17, 2006
Sanofi Aventis Us	ELOXATIN	oxaliplatin	INJECTABLE;INTRAVENOUS	021759-002	Jan 31, 2005
Sanofi Aventis Us	ELOXATIN	oxaliplatin	INJECTABLE;INTRAVENOUS	021759-001	Jan 31, 2005
Sanofi Aventis Us	ELOXATIN	oxaliplatin	INJECTABLE;INTRAVENOUS	021492-002	Aug 9, 2002
Sanofi Aventis Us	ELOXATIN	oxaliplatin	INJECTABLE;INTRAVENOUS	021492-001	Aug 9, 2002

International Patents for ELOXATIN

See the table below for patents covering ELOXATIN around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	H06211883	OPTICALLY HIGH-PURITY CIS-OXALATE@(3754/24)TRANS-1-1,2-CYCLOHEXANEDIAMINE) PLATINUM @(3754/24)II)
Japan	2673331
Spain	2167328
Spain	2125320
Australia	2989695
China	1138541

ELOXATIN Market Analysis and Financial Projection Experimental

Oxaliplatin Market Dynamics and Financial Trajectory: A Focus on ELOXATIN

Introduction to Oxaliplatin and ELOXATIN

Oxaliplatin, marketed under the brand name ELOXATIN by Sanofi, is a crucial chemotherapy drug used primarily in the treatment of colorectal cancer. Here, we will delve into the market dynamics and financial trajectory of the oxaliplatin market, with a specific focus on ELOXATIN.

Global Market Size and Growth

The global oxaliplatin market was valued at USD 965.94 million in 2023 and is projected to reach USD 2,065.74 million by 2032, growing at a CAGR of 8.81% during the forecast period (2024–2032)[1].

Market Drivers

Increasing Prevalence of Cancer

The rising incidence of cancer, particularly colorectal cancer, is a significant driver of the oxaliplatin market. According to the American Cancer Society, there were approximately 147,950 new cases of colorectal cancer diagnosed in 2020 in the United States alone, highlighting the substantial patient base that requires effective treatments like oxaliplatin[1].

Technological Advancements

Technological innovations, such as lyophilization (a freeze-drying technique), have enhanced the stability and shelf life of oxaliplatin, reducing side effects and making it more suitable for clinical use. These advancements are critical in driving growth and innovation within the market[1].

Market Segmentation

By Type

The oxaliplatin market is segmented based on type, including mannitol, glucose solution, lactose solution, and other formulations. ELOXATIN, offered by Sanofi, is available in a lyophilized powder form, which is a preferred option for healthcare professionals due to its enhanced stability[4].

By Application

The market is also segmented by application, with key segments including adjuvant treatment of stage III colon cancer, treatment of stage IV colorectal cancer, and other applications. ELOXATIN is predominantly used in these critical cancer treatment regimens[1].

Regional Market Analysis

North America

North America is the largest market shareholder for oxaliplatin and is expected to expand substantially during the forecast period. The region's growth is driven by increased awareness of cancer treatment options and a rise in colorectal cancer cases. The high incidence of colorectal cancer in the United States underscores the potential demand for ELOXATIN in this region[1].

Asia-Pacific

The Asia-Pacific region is the fastest-growing market for oxaliplatin. This growth is attributed to increasing healthcare spending, improving healthcare infrastructure, and a rising awareness of cancer treatments in the region[1].

Pricing and Affordability

The global average selling price for a 100 mg intravenous injection of oxaliplatin ranges from USD 84 to USD 500. Ensuring fair access to ELOXATIN for all patients, regardless of financial constraints, is crucial. Measures to address affordability and accessibility will be vital in meeting the needs of an expanding patient population and ensuring equitable healthcare delivery[1].

Competitive Landscape

The oxaliplatin market is competitive, with several key players focusing on organic and inorganic growth strategies. Companies are engaging in product launches, product approvals, patents, and partnerships to expand their business and customer base. Sanofi, the manufacturer of ELOXATIN, remains a significant player in this market due to its established brand and continuous innovation in drug formulation and delivery[4].

Financial Performance and Projections

The financial trajectory of the oxaliplatin market, and by extension ELOXATIN, is robust. With a projected CAGR of 8.81%, the market is expected to more than double by 2032. This growth is supported by increasing demand driven by the rising incidence of cancer and advancements in drug technology.

Revenue Projections

• Base Year Market Size: USD 965.94 million (2023)
• Forecast Year Market Size: USD 2,065.74 million (2032)[1]

Regional Revenue Contribution

North America, being the largest market, contributes significantly to the overall revenue. The Asia-Pacific region, however, is expected to grow rapidly, contributing to the market's overall financial performance[1].

Challenges and Opportunities

Affordability and Access

One of the key challenges is ensuring that ELOXATIN is accessible to all patients, particularly those in lower-income regions. Addressing affordability through pricing strategies, government subsidies, or insurance coverage will be essential in expanding the market[1].

Technological Innovations

Technological advancements in drug formulation and delivery present significant opportunities for growth. Innovations like lyophilization not only enhance the drug's stability but also reduce side effects, making ELOXATIN a more viable treatment option[1].

Key Takeaways

• The global oxaliplatin market is expected to grow significantly, driven by the increasing prevalence of cancer and technological advancements.
• ELOXATIN, marketed by Sanofi, is a key player in this market due to its enhanced stability and reduced side effects.
• North America is the largest market shareholder, with the Asia-Pacific region showing the fastest growth.
• Ensuring affordability and access to ELOXATIN is crucial for market expansion.
• Technological innovations continue to drive growth and innovation in the oxaliplatin market.

FAQs

What is the current market size of the global oxaliplatin market?

The global oxaliplatin market was valued at USD 965.94 million in 2023[1].

What is the projected growth rate of the oxaliplatin market?

The oxaliplatin market is expected to grow at a CAGR of 8.81% from 2024 to 2032[1].

Which region is the largest market for oxaliplatin?

North America is the largest market shareholder for oxaliplatin[1].

What are the primary applications of oxaliplatin?

Oxaliplatin is primarily used in the adjuvant treatment of stage III colon cancer and the treatment of stage IV colorectal cancer[1].

How does lyophilization impact the stability of oxaliplatin?

Lyophilization enhances the stability and shelf life of oxaliplatin, reducing the risk of side effects and making it more suitable for clinical use[1].

Sources

1. Straits Research: Oxaliplatin Market Size, Growth & Revenue Analysis Report | 2032
2. Biospace: Eloxx Pharma Secures US$8 Million Investment From LSP ...
3. HUTCHMED: HUTCHMED Reports 2022 Full Year Results and Provides Business ...
4. The Insight Partners: Oxaliplatin Market Insights and Growth by 2031
5. PR Newswire: Eloxx Pharmaceuticals Secures US$8 Million Investment from LSP ...